OverviewSuggest Edit

Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells. 

TypePublic
Founded2007
HQSan Diego, US
Websitekuraoncology.com

Latest Updates

Employees (est.) (Dec 2019)57(+12%)
Job Openings6
Share Price (Sept 2020)$30 (+2%)
Cybersecurity ratingBMore

Key People/Management at Kura Oncology

Kathleen Ford

Kathleen Ford

Chief Operating Officer
Troy Wilson

Troy Wilson

President and Chief Executive Officer, Director
James Basta

James Basta

Chief Legal Officer
Marc Grasso

Marc Grasso

Chief Financial Officer and Chief Business Officer
Francis Burrows

Francis Burrows

Vice President, Translational Research
Pete De Spain

Pete De Spain

Vice President, Investor Relations and Corporate Communications
Show more

Kura Oncology Office Locations

Kura Oncology has offices in San Diego and Boston
San Diego, US (HQ)
3033 Science Park Rd #220
Boston, US
2 Seaport Ln #8a
Show all (2)

Kura Oncology Financials and Metrics

Kura Oncology Revenue

USD

Net income (Q2, 2020)

(20.5m)

Market capitalization (18-Sept-2020)

1.7b

Closing stock price (18-Sept-2020)

30.0

Cash (30-Jun-2020)

134.8m

EV

1.6b
Kura Oncology's current market capitalization is $1.7 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

23.4k22.3k22.7k23.9k19.7m

R&D expense

47.8m

Operating expense total

23.4k22.3k22.7k23.9k67.5m

Depreciation and amortization

20.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

5.8k5.4k4.2k5.0k4.7k4.7k5.5k4.5k4.1k5.2k4.8k1.0m1.5m1.8m7.6m7.5m

R&D expense

2.6m3.3m3.6m12.6m13.7m

Operating expense total

5.8k5.4k4.2k5.0k4.7k4.7k5.5k4.5k4.1k5.2k4.8k3.6m4.8m5.4m20.2m21.2m

EBIT

(5.8k)(5.4k)(4.2k)(5.0k)(4.7k)(4.7k)(5.5k)(4.5k)(4.1k)(5.2k)(4.8k)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.2k4.8k6.6k5.6k15.4m9.7m11.4m16.1m26.1m

Accounts Receivable

92.4m

Prepaid Expenses

2.5k3.5k2.5k693.0k1.3m2.0m2.7m

Inventories

725.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

9.3k6.2k23.7k9.5k5.6k2.9k18.7k10.6k6.2k4.9k18.2k53.6m19.8m11.2m16.3m12.1m6.8m10.6m12.2m23.3m26.5m17.7m20.6m17.8m122.1m54.7m33.8m134.8m

Accounts Receivable

31.0k

Prepaid Expenses

6.3k4.4k625.06.3k5.9k1.1k4.4k625.0707.0k884.0k695.0k1.2m1.0m886.0k1.1m1.2m909.0k1.9m2.4m2.7m1.9m2.4m2.8m4.2m3.3m

Current Assets

15.5k10.5k24.4k15.7k11.5k4.0k54.6m47.2m42.3m80.1m81.4m75.7m60.6m54.7m101.9m140.4m128.5m190.4m167.6m263.9m252.9m221.1m342.2m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(27.0k)(27.3k)(28.6k)(30.7k)(22.6m)(27.6m)(35.4m)(60.4m)(63.1m)

Depreciation and Amortization

20.0k31.0k30.0k10.0k

Accounts Payable

762.0(1.1k)(1.5k)2.1k2.8m856.0k

Cash From Operating Activities

(22.7k)(24.4k)(23.2k)(16.0k)(17.9m)(25.3m)(28.4m)(48.7m)(54.8m)
Show all financial metrics

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials Products

1

Pre-Clinical Phase Products

2
Show all operating metrics

Kura Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Kura Oncology Online and Social Media Presence

Embed Graph

Kura Oncology News and Updates

Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Officer. Dr. Dale joins…

Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology Forum…

Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –

Kura Oncology to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference. Troy Wi…

Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer

Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –
Show more

Kura Oncology Blogs

Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual

Kura Oncology to Report Second Quarter 2020 Financial Results

Kura Oncology to Report Second Quarter 2020 Financial Results Content Import Thu, 07/30/2020 - 07:30 Kura Oncology to Report Second Quarter 2020 Financial Results July 30, 2020 at 7:30 AM EDT This release is a backfill from a News Wire General …

Institut Gustave Roussy

Villejuif, France, 94800

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States, 98109

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States, 14263
Show more

Kura Oncology Frequently Asked Questions

  • When was Kura Oncology founded?

    Kura Oncology was founded in 2007.

  • Who are Kura Oncology key executives?

    Kura Oncology's key executives are Kathleen Ford, Troy Wilson and James Basta.

  • How many employees does Kura Oncology have?

    Kura Oncology has 57 employees.

  • Who are Kura Oncology competitors?

    Competitors of Kura Oncology include FORMA Therapeutics, Oncomatryx and Oxford Cancer Biomarkers.

  • Where is Kura Oncology headquarters?

    Kura Oncology headquarters is located at 3033 Science Park Rd #220, San Diego.

  • Where are Kura Oncology offices?

    Kura Oncology has offices in San Diego and Boston.

  • How many offices does Kura Oncology have?

    Kura Oncology has 2 offices.